402 related articles for article (PubMed ID: 31329849)
1. Incidence of appropriate implantable cardioverter-defibrillator therapy and mortality after implantable cardioverter-defibrillator generator replacement: results from a real-world nationwide cohort.
Ruwald MH; Ruwald AC; Johansen JB; Gislason G; Nielsen JC; Philbert B; Riahi S; Vinther M; Lindhardt TB
Europace; 2019 Aug; 21(8):1211-1219. PubMed ID: 31329849
[TBL] [Abstract][Full Text] [Related]
2. Outcomes After Implantable Cardioverter-Defibrillator Generator Replacement for Primary Prevention of Sudden Cardiac Death.
Madhavan M; Waks JW; Friedman PA; Kramer DB; Buxton AE; Noseworthy PA; Mehta RA; Hodge DO; Higgins AY; Webster TL; Witt CM; Cha YM; Gersh BJ
Circ Arrhythm Electrophysiol; 2016 Mar; 9(3):e003283. PubMed ID: 26921377
[TBL] [Abstract][Full Text] [Related]
3. Benefit of Implantable Cardioverter-Defibrillator Generator Replacement in a Primary Prevention Population-Based Cohort.
Weng W; Sapp J; Doucette S; MacIntyre C; Gray C; Gardner M; Abdelwahab A; Parkash R
JACC Clin Electrophysiol; 2017 Oct; 3(10):1180-1189. PubMed ID: 29759503
[TBL] [Abstract][Full Text] [Related]
4. The Occurrence of Implantable Cardioverter Defibrillator Therapies After Generator Replacement in Patients Who No Longer Meet Primary Prevention Indications.
Kawata H; Hirai T; Doukas D; Hirai R; Steinbrunner J; Wilson J; Noda T; Hsu J; Krummen D; Feld G; Wilber D; Santucci P; Birgersdotter-Green U
J Cardiovasc Electrophysiol; 2016 Jun; 27(6):724-9. PubMed ID: 26915696
[TBL] [Abstract][Full Text] [Related]
5. Risk of Appropriate Therapy and Death Before Therapy After Implantable Cardioverter-Defibrillator Generator Replacement.
Witt CM; Waks JW; Mehta RA; Friedman PA; Kramer DB; Buxton AE; Mulpuru SK; Noseworthy PA; Hodge DO; Lushinsky EC; Mulholland MB; Cha YM; Gersh BJ; Madhavan M
Circ Arrhythm Electrophysiol; 2018 Aug; 11(8):e006155. PubMed ID: 30354311
[TBL] [Abstract][Full Text] [Related]
6. Mortality Implications of Appropriate Implantable Cardioverter Defibrillator Therapy in Secondary Prevention Patients: Contrasting Mortality in Primary Prevention Patients From a Prospective Population-Based Registry.
Almehmadi F; Porta-Sánchez A; Ha ACT; Fischer HD; Wang X; Austin PC; Lee DS; Nanthakumar K
J Am Heart Assoc; 2017 Aug; 6(8):. PubMed ID: 28862957
[TBL] [Abstract][Full Text] [Related]
7. Prophylactic implantable cardioverter defibrillators for primary prevention: From implantation to heart transplantation.
Algalarrondo V; Perault R; Bories MC; Narayanan K; Garcia R; Combes N; Perier MC; Defaye P; Sadoul N; Gras D; Klug D; Bordachar P; Fauchier L; Deharo JC; Leclercq C; Boveda S; Marijon E; Babuty D;
Arch Cardiovasc Dis; 2018 Dec; 111(12):758-765. PubMed ID: 30078651
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcome in patients with implantable cardioverter-defibrillator and cancer: a nationwide study.
Christensen AM; Bjerre J; Schou M; Jons C; Vinther M; Gislason GH; Johansen JB; Nielsen JC; Petersen HH; Riahi S; Ruwald AC
Europace; 2019 Mar; 21(3):465-474. PubMed ID: 30535192
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the need of elective implantable cardioverter-defibrillator generator replacement in primary prevention patients without prior appropriate ICD therapy.
Yap SC; Schaer BA; Bhagwandien RE; Kühne M; Dabiri Abkenari L; Osswald S; Szili-Torok T; Sticherling C; Theuns DA
Heart; 2014 Aug; 100(15):1188-92. PubMed ID: 24993502
[TBL] [Abstract][Full Text] [Related]
10. Risk of subsequent ventricular arrhythmia is higher in primary prevention patients with implantable cardioverter defibrillator than in secondary prevention patients.
Zhou Y; Zhao S; Chen K; Hua W; Su Y; Chen S; Liang Z; Xu W; Zhang S
BMC Cardiovasc Disord; 2019 Oct; 19(1):230. PubMed ID: 31638918
[TBL] [Abstract][Full Text] [Related]
11. Time dependence of risks and benefits in pediatric primary prevention implantable cardioverter-defibrillator therapy.
DeWitt ES; Triedman JK; Cecchin F; Mah DY; Abrams DJ; Walsh EP; Gauvreau K; Alexander ME
Circ Arrhythm Electrophysiol; 2014 Dec; 7(6):1057-63. PubMed ID: 25262116
[TBL] [Abstract][Full Text] [Related]
12. Association Between Comorbidities and Outcomes in Heart Failure Patients With and Without an Implantable Cardioverter-Defibrillator for Primary Prevention.
Khazanie P; Hellkamp AS; Fonarow GC; Bhatt DL; Masoudi FA; Anstrom KJ; Heidenreich PA; Yancy CW; Curtis LH; Hernandez AF; Peterson ED; Al-Khatib SM
J Am Heart Assoc; 2015 Aug; 4(8):e002061. PubMed ID: 26251283
[TBL] [Abstract][Full Text] [Related]
13. Predictors of appropriate shock after generator replacement in patients with an implantable cardioverter defibrillator.
Arcinas LA; Chew DS; Seifer CM; Baranchuk A; Supel I; Exner DV; Boles U; McIntyre WF
Pacing Clin Electrophysiol; 2021 May; 44(5):911-918. PubMed ID: 33826179
[TBL] [Abstract][Full Text] [Related]
14. Normalization of Left Ventricular Ejection Fraction and Incidence of Appropriate Antitachycardia Therapy in Patients With Implantable Cardioverter Defibrillator for Primary Prevention of Sudden Death.
House CM; Nguyen D; Thomas AJ; Nelson WB; Zhu DW
J Card Fail; 2016 Feb; 22(2):125-32. PubMed ID: 26522819
[TBL] [Abstract][Full Text] [Related]
15. Propensity score matched comparison of subcutaneous and transvenous implantable cardioverter-defibrillator therapy in the SIMPLE and EFFORTLESS studies.
Brouwer TF; Knops RE; Kutyifa V; Barr C; Mondésert B; Boersma LVA; Lambiase PD; Wold N; Jones PW; Healey JS
Europace; 2018 Sep; 20(FI2):f240-f248. PubMed ID: 29771327
[TBL] [Abstract][Full Text] [Related]
16. Appropriate implantable cardioverter-defibrillator interventions in cardiac resynchronization therapy-defibrillator (CRT-D) patients undergoing device replacement: time to downgrade from CRT-D to CRT-pacemaker? Insights from real-world clinical practice in the DECODE CRT-D analysis.
Narducci ML; Biffi M; Ammendola E; Vado A; Campana A; Potenza DR; Iori M; Zanon F; Zacà V; Zoni Berisso M; Bertini M; Lissoni F; Bandini A; Malacrida M; Crea F
Europace; 2018 Sep; 20(9):1475-1483. PubMed ID: 29186401
[TBL] [Abstract][Full Text] [Related]
17. The impact of co-morbidity burden on appropriate implantable cardioverter defibrillator therapy and all-cause mortality: insight from Danish nationwide clinical registers.
Ruwald AC; Vinther M; Gislason GH; Johansen JB; Nielsen JC; Petersen HH; Riahi S; Jons C
Eur J Heart Fail; 2017 Mar; 19(3):377-386. PubMed ID: 27905161
[TBL] [Abstract][Full Text] [Related]
18. Incidence of and predictors for appropriate implantable cardioverter-defibrillator therapy in patients with a secondary preventive implantable cardioverter-defibrillator indication.
Schaer B; Kühne M; Reichlin T; Osswald S; Sticherling C
Europace; 2016 Feb; 18(2):227-31. PubMed ID: 26063686
[TBL] [Abstract][Full Text] [Related]
19. Importance of beta-blocker dose in prevention of ventricular tachyarrhythmias, heart failure hospitalizations, and death in primary prevention implantable cardioverter-defibrillator recipients: a Danish nationwide cohort study.
Ruwald AC; Gislason GH; Vinther M; Johansen JB; Nielsen JC; Philbert BT; Torp-Pedersen C; Riahi S; Jøns C
Europace; 2018 Sep; 20(FI2):f217-f224. PubMed ID: 29684191
[TBL] [Abstract][Full Text] [Related]
20. Outcomes in African Americans undergoing cardioverter-defibrillator implantation for primary prevention of sudden cardiac death: findings from the Prospective Observational Study of Implantable Cardioverter-Defibrillators (PROSE-ICD).
Zhang Y; Kennedy R; Blasco-Colmenares E; Butcher B; Norgard S; Eldadah Z; Dickfeld T; Ellenbogen KA; Marine JE; Guallar E; Tomaselli GF; Cheng A
Heart Rhythm; 2014 Aug; 11(8):1377-83. PubMed ID: 24793459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
